Odyssey Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ODTX | ACRS | CRVS | ANNX | OBX | OMER | |
|---|---|---|---|---|---|---|
| Market cap | 877.55M | 529.92M | 845.42M | 750.73M | 790.08M | 1.42B |
| P/E (TTM) | — | — | — | — | — | 16.1 |
| Forward P/E | -4.4 | -4.6 | -9.4 | -3.6 | -6.0 | 16.0 |
| Price/book | 2.1 | 4.0 | 3.8 | 3.7 | -1.0 | -27.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +15.71% | +88.48% | +47.96% | +32.00% | −25.71% | +373.27% |
| Today | −3.89% | −6.01% | −4.47% | −1.49% | −1.62% | −1.01% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ODTX news ›Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
The planned study pairs combination induction treatment with maintenance using OD-001 alone through Week 52. Odyssey Therapeutics (Nasdaq: ODTX) will present its Phase 2a trial design for OD-001 combined with vedolizumab in ulcerative…
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Average Target Price of $35.75
Posted by Sarita Garza on Oct 8th, 2026 Read Our Latest Report on Odyssey Therapeutics Odyssey Therapeutics (NASDAQ:ODTX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.74)…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketbeat.com1
-
themarketsdaily.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.